Abstract: Inherited retinal diseases (IRDs) are a major cause of incurable familial blindness in the Western world. In the pediatric population, IRDs are a major contributor to the 19 million children worldwide with visual impairment. Unfortunately, the road to the correct diagnosis is often complicated in the pediatric population, as typical diagnostic tools such as fundus examination, electrodiagnostic studies, and other imaging modalities may be difficult to perform in the pediatric patient. In this review, we describe the most significant IRDs with onset during the pediatric years (ie, before the age of 18). We describe the pathogenesis, clinical presentation, and potential treatment of these diseases. In addition, we advocate the use of a pedigree (family medical history), electroretinography, and genetic testing as the 3 most crucial tools for the correct diagnosis of IRDs in the pediatric population.
I
nherited retinal disorders (IRDs) are a major cause of incurable familial blindness in the Western world. 1 In the pediatric population, it is estimated that 19 million children worldwide are visually impaired. 2 Collectively, IRDs are an important contributor to visual impairment in the pediatric population. 2 For example, the British Childhood Visual Impairment Study found that 24% of childhood visual impairments were due to retinal problems. 3 Furthermore, though these dystrophies may present in isolation or as part of a systemic syndrome, the retinal disorders often are the first presenting features of a systemic disorder. 4 Additionally, syndromic retinal dystrophies account for approximately 20-30% of all retinal dystrophies. 5 Thus, identification and correct diagnosis of retinal disorders are crucial for proper treatment.
Inherited retinal disorders can practically be classified into the following 3 categories based on the origin and function of the disease-causing gene: 1) diseases of the photoreceptors; 2) macular dystrophies; and 3) disorders of other origin (eg, choroidopathies, vitreoretinopathies, albinism, and retinoschisis). As such, we present in this review the most significant pediatric onset (ie, before 18 years of age) IRDs in the 3 broad categories. Of note, photoreceptor dystrophies have been reported to be the most common IRD among pediatric patients with visual impairments. 6 For the described IRDs, we describe the pathogenesis, spectrum of clinical presentation, and treatment options or ongoing clinical trials. In diagnosis, the importance of a patient and family medical history, electrodiagnostic studies, and genetic sequencing are emphasized. The correct clinical diagnosis is crucial for a more accurate disease prognosis, possible association with a systemic syndrome, and inclusion potential for treatment clinical trials.
IMPORTANT TOOLS IN CLINICAL DIAGNOSIS
With young children, patient cooperation in testing of vision, imaging, and fundus examination may prove to be difficult. As such, initial tools to reach a clinical diagnosis of the IRD in question in the pediatric population involve electroretinography (ERG), patient and family medical history, and genetic sequencing. Electroretinography has been shown to be an invaluable tool in producing a diagnosis and prognosis. 7 In a study from a tertiary pediatric hospital, ERG testing helped to confirm, exclude, change, or provide a new diagnosis in 85% of the 318 cases studied. 7 Even still, performing ERGs on the pediatric population can be difficult, as a child may object to an unfamiliar test that involves electrodes being placed on the surface of the eye or near the eye. As a result, traditionally ERGs have often been performed under sedation when necessary. However, recent development of handheld ERG devices has further decreased the need to sedate children. 8 In a study of 71 children at a tertiary pediatric center, amplitudes and implicit times were successfully obtained in 65 children, including 34 with nystagmus, via cone flicker ERG. 8 With the appropriate technique and modern equipment, an ERG reading may be obtained in a nontraumatic manner for the pediatric patient.
Given the genetic nature of these conditions, a pedigree is an essential diagnostic tool (Fig. 1) . Any history of similar eye symptoms in the family should be carefully assessed for inheritance patterns that may help narrow the diagnostic possibilities. In general, a comprehensive, 3-generation pedigree is recommended. In addition, the clinician should ask about any history of consanguinity in the family, as a constricted genetic pool increases the likelihood of autosomal recessive retinal dystrophies. If possible, examination of parents, siblings, or other relatives can provide important diagnostic information. In X-linked diseases such as choroideremia or X-linked retinitis pigmentosa, for example, female carriers present with characteristic fundus findings that may suggest a particular diagnosis. [9] [10] [11] Other considerations are ethnicity or geographic associations, as some inherited retinal disease alleles are more common in certain populations. Bietti crystalline dystrophy is such an example, as it is more common in Asian populations. 12 Finally, antenatal, birth, and growth history can also provide crucial information towards the correct diagnosis. History of prior and current medical problems and surgeries should be investigated. A history of surgical amputation of extra digits, for example, would suggest to the experienced clinician the possibility of Bardet-Biedl syndrome, whereas a history of hearing impairment suggests the possibility of Usher syndrome.
Great advances in high-throughput DNA sequencing technologies have revolutionized the field of ophthalmic genetics in the last decade. Genetic testing for IRDs has become a standard approach to facilitate obtaining an accurate and definitive diagnosis. In addition, genetic testing has helped the clinician in assessing the risk of disease for family members, planning appropriate genetic counseling for the families, and determining inclusion of the patient in clinical trials. 13 Over the past 2 decades, more than 200 IRD-causative genes have been identified. 13 In identifying the causative gene for a patient's disease, multiple studies have demonstrated the effectiveness and sensitivity of panel-based genetic testing. [14] [15] [16] [17] In one study, in comparison to whole exome sequencing, panel-based testing was found to be more sensitive for detection of disease-causing genetic variants.
14 In a study of 85 children with a diagnosis of IRD, panel-based testing yielded a diagnosis in 84.7% of the cases. 15 In contrast, in a study of 26 patients with a diagnosis of IRD, the diagnostic yield of whole exome sequencing in identifying known pathogenic mutations or deleterious variants was 57.7%. 16 The largest study to date exploring the different platforms of genetic testing was performed on 1000 families with IRDs, where disease-causing phenotypes were identified in 76% of the families. 16 This study reports that a tier-testing strategy, proceeding from single gene candidates to panel-based testing to whole exome, can increase the sensitivity in identifying disease-causing phenotypes without increasing the cost. 17 Overall, genetic testing, ERG, and a thorough family medical history are the most important tools for the IRD diagnosis in the pediatric population.
PHOTORECEPTOR DISEASES Leber Congenital Amaurosis
Leber congenital amaurosis (LCA), also known as early onset retinal dystrophy, is one of the most severe retinal dystrophies as there is generalized retinal degeneration at birth, causing severe vision impairment before the age of 1. Despite its severity, it is a rare dystrophy, with prevalence estimated to be between 1 in 30,000 and 1 in 81,000. 18, 19 Nevertheless, LCA accounts for at least 5% of all inherited retinopathies and approximately 20% of children attending schools for the blind. 19 Most often, LCA is inherited in an autosomal recessive manner. Currently, 14 genes have been identified as LCA-causative, and these genes account for approximately 70% of the cases. 18 From these 14 genes, the most frequently mutated are CEP290 (15%), GUCY2D (12%), and CRB1 (10%). 18 The genes IMPDH1 and RPE65 are other common causes of LCA. All of these genes encode proteins for a variety of photoreceptor functions: photoreceptor morphogenesis (CRB1), phototransduction (GUCY2D), guanine synthesis (IMPDH1), intraphotoreceptor ciliary transport (CEP290), and vitamin A recycling (RPE65). 18 Clinically, LCA classically presents early in life, usually around week 6 with severe visual loss, nystagmus, and amaurotic pupils. Keratoconus, high hyperopia, cataracts, and intellectual disability are also often associated with LCA. Visual acuity mostly ranges from 20/200 to light perception, although acuities of 20/50 have been reported with mutations in the genes RPE65, CRB1, and LRAT. 20 The severity and the progression of visual acuity loss seem to be correlated to genotype. Patients with mutations in RPE65, CRB1, and LRAT exhibit mild improvements in visual function temporarily, followed by a period of stability in their visual function before later declining; whereas patients with mutations in AILP1 and RPGRIP1 have a progressive course of degeneration. 20 Patients with mutations in CEP290 and GUCY2D, however, often exhibit stable but severe vision loss. 20 Useful clinical imaging tools for diagnosing LCA include ERG, spectral domain optical coherence tomography (SD-OCT) scans, and fundus autofluorescence (FAF) imaging. Electroretinography responses are usually severely diminished and nonrecordable. In patients with mutations in CRB1, SD-OCT classically shows a thickened retina without the normal lamination of its layers, with a reduced outer nuclear layer at the central fovea (Fig. 2) . 21 Fundus autofluorescence findings tend to depend on genotype, as with RPE65 mutations, absent or minimal autofluorescence is seen in patients, whereas with mutations on GUCY2D, FAF appears normal. 18 The appearance of the retina in fundoscopy exhibits a large degree of variability. 18 Gene supplementation therapy has been widely studied as a form of treatment for IRDs, and RPE65-mediated LCA is at the forefront of these studies. The principle behind gene therapy is that in a person with a recessively inherited IRD, with 2 recessive mutations needed for expression of disease phenotype, therapeutic introduction of a single wild-type allele can give cells sufficient expression of a normal gene product. A gene supplementation-based therapy requires the preservation of cells, as it does not replace cells but only replaces a gene. Fortunately in RPE65 LCA, even with severe visual impairment, retinal and photoreceptor cells are relatively preserved, in stark contrast to other phenotypes of LCA, making RPE65 a reasonable candidate for gene supplementation therapy. 20 Preclinical studies of RPE65 gene therapy began with animal models, namely Briard dogs. After injecting an adeno-associated virus (AAV2) containing the RPE65 complementary DNA into the subretinal space of 1 eye, there was a dramatic restoration of ERG responses and 50% increase in light sensitivity, along with improvement in other measures of visual function. 20 After observing encouraging results in terms of safety and efficacy from the preclinical animal studies, investigators at 3 different institutions commenced an initial phase clinical trial with a total of 9 patients; the results were published in 2008. [22] [23] [24] [25] Although no improvements were seen in ERG responses, 7 patients reported significant increases in light perception, 3 demonstrated significant improvement in visual acuity, and greater pupillary response to light was observed in all patients. [22] [23] [24] [25] No significant adverse effects were reported. Future studies focused on the longterm effect of gene therapy and reported improvements in retinal sensitivity that were found to be transient and lasted around 3 years. 26 More recently, results from a phase 3 randomized controlled trial with an intervention group of 20 patients showed that gene replacement improved visual function without serious adverse effects or immune responses. 27 Overall, the results from multiple trials for gene therapy of RPE65 have shown the approach to be both safe and effective. 28 The results from these trials are landmarks in the treatment of IRDs with gene therapy and will influence the expansion of this treatment modality to IRDs caused by other genes.
X-Linked Retinitis Pigmentosa
Retinitis pigmentosa (RP) refers to a group of IRDs characterized by progressive nyctalopia and constricting visual fields, caused by rod degeneration eventually affecting the cones. 29 Retinitis pigmentosa has a worldwide prevalence of 1 in 4000. 29 Most types of RP are inherited in Mendelian patterns: autosomal dominant, autosomal recessive, and X-linked. From these forms, X-linked retinitis pigmentosa (XLRP) is usually the most severe subtype, almost exclusively affecting males. Patients begin manifesting symptoms of nyctalopia and field constriction within the first 2 decades of life, progressing to severe visual loss and even blindness by the third or fourth decade of life. In comparison to autosomal dominant RP (adRP), considered to be the least severe subtype, the median age of legal blindness in XLRP patients is 32 years younger. 30 It is estimated that XLRP contributes to 5-15% of RP cases. 29 The vast majority of XLRP cases are caused by mutations in 2 genes: RPGR (70-80%) and RP2 (7-10%). 29 Other potential genes have been mapped by linkage analysis to the X chromosome but have not yet been concretely identified. 29 Studies have shown that most mutations in RPGR are located in a "mutational hot spot," exon ORF15, with mutations in ORF15 causing over 50% of XLRP. [30] [31] [32] The protein products of both RPGR and RP2 are components of the photoreceptor-connecting cilium and play a crucial role in protein trafficking to the outer segments. 33 The genotype of XLRP influences the clinical progression of the disease and long-term visual prognosis. It has been reported that at a given age, patients with mutations in RP2 retain less visual acuity as compared with patients with RPGR mutations, and among RPGR patients, those with mutations in ORF15 have milder disease than those with mutations in exons 1-14. 30 An initial diagnosis of XLRP can be suggested based on family history, classic clinical findings observed in RP, and ERG. Given the X-linked inheritance, the disease mostly manifests in males. Female carriers of RPGR mutations can exhibit symptoms, but they tend to be milder than in males, often asymptomatic until late adulthood. However, imaging of the carrier female often shows a carrier sign known as the tapetal-like fundus reflex in the perimacular region, appreciated as a pattern of hyperreflective radial lines (Fig. 2) . 9, 34 Thus, when an X-linked inheritance pattern is noticed upon family history, imaging of the potential carrier mother can expedite diagnosis. Fundus autofluorescence imaging may also identify female carriers. 11 Other clinical findings that point the clinician towards RP diagnosis upon examination include attenuation of the vessels, bone-spicule intraretinal pigment migration, symptoms of constricting visual field, and nyctalopia (Fig. 2) . The ERG would show a rod-cone pattern, with the rods much more affected than the cones. If the pediatric patient is cooperative, other important clinical imaging such as SD-OCT and FAF can be performed. Spectral domain OCT scans may reveal peripheral thinning of the outer retinal layers and disruption of the ellipsoid zone, whereas FAF may show areas of peripheral hypoautofluorescence www.apjo.org | 185 along with a central hyperautofluorescent ring. As in other subtypes of RP, there is currently no treatment available to the general population; nonetheless, a gene replacement therapy clinical trial of the RPGR gene via AAV vector delivery is underway (ClinicalTrials.gov identifier: NCT03252847).
Syndromic Retinitis Pigmentosa
Although RP is a retinal dystrophy, around 20-30% of patients also have an associated nonocular disease. 29 During the visual exam, the clinician may note other signs in addition to RP that would suggest the diagnosis of a particular syndrome.
Usher Syndrome
Usher syndrome is an inherited autosomal recessive condition presenting with RP and bilateral neurosensory hearing loss. 35 It is the most common cause of hereditary blindness-deafness, accounting for approximately 50% of all such cases. Usher syndrome has a prevalence of 3 to 6:100,000. 36, 37 Usher syndrome is characterized clinically into 3 subtypes based on the onset and progression of hearing loss. Usher 1 presents with congenital hearing loss, childhood onset RP, and possible vestibular dysfunction. 35, 36 Usher 2 is characterized by congenital, nonprogressive, mild to severe hearing loss, in addition to onset of RP early in adulthood. 35, 36 Usher 3 is the rarest, presenting with mild and progressive hearing loss and variable onset of RP, with variable vestibular dysfunction. 35, 36 A fourth subtype has been suggested to group the atypical forms, but this subtype is still under debate. 37 Ten causal genes have been identified for the classic Usher 1-3 syndromes. 37, 38 There are 6 for Usher 1: MYO7A (most common), CDH23, PCDH15, USH1C, USH1G, and CIB238; 3 for Usher 2: USH2A (most common), GPR98, and WHRN; and 1 for Usher 3: CLRN1. All of these genes are involved in ciliary transport or scaffolding proteins important for cellular structure and morphology of photoreceptors and inner ear hair cells. 35, 38 A comparison of retinal disease progression between Usher 1 patients with MYO7A mutations and Usher 2 patients with USH2A mutations has shown that Usher 1 patients experience earlier onset of symptoms and more severe retinal disease progression.
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Bardet-Biedl Syndrome
Bardet-Biedl syndrome (BBS) is an autosomal recessive disorder characterized by primary clinical features of retinal degeneration in the form of RP, polydactyly, obesity, learning disabilities, hypogonadism in males, and renal abnormalities. 39 Secondary clinical features include speech disorders, developmental delay, diabetes insipidus, brachydactyly or syndactyly, ataxia, dental crowding/hypodontia, and congenital heart diseases. 39 Clinical diagnosis of BBS requires the presence of at least 4 primary features or a combination of 3 primary and at least 2 secondary features. 39 The prevalence of BBS ranges from 1:160,000 in Northern Europe to 1:13,500 in Kuwait and Newfoundland. 40 To date, 15 genes have been associated with BBS, including BBS1-12 and CEP290. 39, 40 All of these identified causative genes code for proteins involved with cilia, making BBS a member of the ciliopathy diseases. The most common cause of BBS is the BBS1 gene, with the mutation M390R found in approximately 80% of BBS1-induced mutations. 41 BBS1, 2, 4, 5, 7, 8 , and 9 are highly conserved and their protein products form what is called the "BBSome," which works with the protein Rab8 to promote the biogenesis of cilia in the retinal pigment epithelium (RPE). 41 FIGURE 2. Classical clinical findings of the photoreceptor diseases. In RP, clinical findings in the posterior pole include bone-spicule intraretinal pigment migration, attenuation of blood vessels, and a waxy appearance to the optic disc (A). Additionally, FAF often reveals a ring of hyperautofluorescence in the macular area (B). On SD-OCT, there is peripheral thinning of the outer retinal layers and disruption of the ellipsoid zone (red arrows) (C). In female carriers of a mutated RPGR allele, 488 nm, red-free reflectance imaging shows a tapetallike reflex (D), which is a pattern of hyperreflective radial lines in the perimacular area (E). The appearance of a hyperautofluorescent ring in XLRP is variable, and in those patients that present it, the appearance varies from a classical ring (F) to a nonclassical, wider ring (G). In LCA patients with mutations in CRB1, SD-OCT presents a thickened retina without the normal lamination of its layers (H). Classical presentation of an optical gap in a patient with achromatopsia (I). SD-OCT reveals loss of the photoreceptor layer in the foveal region and disruption on the inner/outer segment junction (red arrow).
BBS6, 10, and 12 are chaperonin-like proteins and mediate the assembly of the BBSome. 42 Bardet-Biedl syndrome can be a difficult diagnosis as it exhibits a great degree of clinical and genetic heterogeneity. In addition to the multiple genes causing BBS, the degree of severity of RP in these patients has been shown to vary from mild to severe. 41 
Senior-Locken Syndrome
Senior-Locken syndrome (SLS) is an autosomal recessive disorder characterized by nephronophthisis and RP. 43 Nephronophthisis is a medullary cystic kidney disease that constitutes the most frequent cause of genetic end-stage renal disease in children and adolescents. 43 Initial symptoms can be mild and start at around 6 years of age. The symptoms can include polyuria, polydipsia, anemia, and secondary enuresis. Renal failure manifests at a median age of 13 years. 44 Nephronophthisis is caused by mutations in the nephrocystin genes, NPHP1-13, but only NPHP1-9 are associated with retinal degenerations. 43 Senior-Locken syndrome is also considered a ciliopathy, as the nephrocystin proteins are involved in connecting cilia of photoreceptors in the retina and primary cilia of renal epithelial cells. 44 Although mutations in any of the NPHP genes can cause nephronophthisis, only mutations in NPHP5 always present with both retinal and renal involvement. 44 Identification of renal disease in children or adolescents should prompt a retinal examination.
Achromatopsia (Rod Monochromatism)
Congenital achromatopsia (ACHM) is an autosomal recessive disorder of cone signal transduction with a prevalence of 1 in 30,000 people worldwide. 45 To date, 6 causative genes (CNGA3, CNGB3, GNAT2, PDE6C, PDE6H, and ATF6) have been identified in ACHM patients, with CNGA3 and CNGB3 mutations accounting for approximately 70% of all cases. 46 These genes encode crucial components of the cone phototransduction cascade. The CNGA3 and CNGB3 genes encode a member of the cyclic nucleotide-gated ion channel protein family, which are critical for normal vision in cone photoreceptors. 47 Signs and symptoms vary as cases range clinically from complete (typical) to incomplete (atypical) achromatopsia, depending on the amount of residual cone function. 48 In typical complete achromatopsia, patients present usually by 6 months old with photophobia and nystagmus. Visual acuity is typically less than 20/200 for those with complete achromatopsia but may be as good as 20/80 for those with incomplete achromatopsia. Although nystagmus may become less noticeable over time, visual acuity is usually stable. Additional symptoms may include a small central scotoma with eccentric fixation.
Clinical diagnosis of achromatopsia can be made through clinical and family history, examination for nystagmus, visual acuity testing, color vision assessment, fundoscopic examination, and ERG. Additional testing may include optical coherence tomography (SD-OCT) and visual fields. On fundoscopic examination there may be narrowing of blood vessels, RPE mottling, or alteration of the foveal reflex. Visual field examination often shows a relative central scotoma, but this may be difficult to elucidate in the setting of unsteady fixation.
Electroretinography is the most common test of retinal function in suspected patients. Full-field ERG does not often show pathologic changes because of the limited number of photoreceptors within the fovea as compared with the entire retina. About 75% of patients with achromatopsia have a normal full-field ERG response. 49 Multifocal ERG (mfERG) is a more precise diagnostic tool for evaluation of achromatopsia as it eliminates contribution of the extramacular retina. Absent response from a 30-or 15-Hz stimulus in the cone-driven pathway on mfERG supports the diagnosis of achromatopsia. However, mfERG may not be sensitive enough to confidently differentiate between complete and incomplete achromatopsia. 49, 50 Spectral domain OCT is another useful diagnostic technique; Genead et al 49 demonstrated that approximately 85% of achromatopsia patients have some degree of disruption of photoreceptors on SD-OCT. Spectral domain OCT generally exhibits 3 features: loss of the photoreceptor layer in the foveal region and disruption of the inner/outer segment junction (referred to as an optical gap), foveal hypoplasia, and macular thinning (Fig. 2) . Testing color vision is helpful in characterizing the ACHM phenotype. Patients with achromatopsia demonstrate abnormalities in all axes, but the test becomes unreliable as patients may begin to discern colors based on differences in brightness (using their undamaged rod photoreceptors) or learned associated object-color relationships.
There is no cure for achromatopsia. The management of symptoms and associated findings is important for a better quality of life. Regular ophthalmic examination is recommended every 6 to 12 months in children to optimize refraction. Extreme photophobia is possible even in low light settings. Avoidance of light, visors, specialized filtered glare control lenses, or red/ gray/amber-tinted eyeglasses are used to help to reduce photophobia and subjectively improve visual acuity. Currently, gene therapy trials are underway. One phase 1/2 clinical trial will inject AAV expressing CNGA3 in patients with congenital ACHM (ClinicalTrials.gov identifier: NCT02935517), whereas a second trial will inject AAV expressing CNGB3 (ClinicalTrials.gov identifier: NCT02599922). Another phase 1/2 trial is currently recruiting patients for a safety and efficacy study for AAV-mediated delivery of CNGB3 to adults and children with congenital achromatopsia caused by mutations in the CNGB3 gene (ClinicalTrials.gov identifier: NCT03001310).
MACULAR DYSTROPHIES Stargardt Disease
Stargardt macular dystrophy is the most common form of juvenile-onset macular degeneration with a prevalence of 1 in 10,000. 51, 52 It was first described by Karl Stargardt in 1909 and Franceschetti first introduced the term "funds flavimaculatus" in 1963, which referred to the yellow-white flecks in the deep retinal layers of the posterior pole. 53 It is caused by mutations in the ABCA4 gene and inherited in an autosomal recessive pattern.
51 ABCA4 protein dysfunction causes accumulation of all-trans-retinal, a byproduct of photoreceptor metabolism, in the photoreceptors and in the RPE. All-trans-retinal is then converted to N-retinylidene-N-retinylethanolamine (A2E), a principal component of lipofuscin, which is toxic to RPE and photoreceptors. 54 Patients present with central visual loss in teenage years and ophthalmoscopy classically reveals macular atrophy with yellowish-white flecks at the posterior pole at the level of the RPE, with variable fundus appearance (Fig. 3) . 51 Cases with childhood-onset disease are associated with more severe visual acuity loss from the early stages of disease. The classical flecks are not always present at diagnosis but can appear later in the course of the disease. 55 Visual acuity loss may precede ophthalmoscopic abnormalities in childhood-onset disease. In such cases, SD-OCT imaging with disruption of foveal outer retinal layers and ERG with generalized rod and cone system dysfunction can help avoid misdiagnosis. 56 Stargardt macular dystrophy has been classified into 3 groups based on ERG. 55 Group 1 patients present with dysfunction confined to the macula. Group 2 patients have macular and generalized cone dysfunction. Group 3 patients have macular and both generalized cone and rod dysfunction. 55 A study showed that a greater proportion of children with Stargardt were in group 3 as compared with adults and also indicated that childhood-onset disease is more likely to be associated with generalized retinal dysfunction and a more severe disease phenotype. 55 Many therapies for Stargardt under investigation are aimed at restricting all-trans-retinal and consequently the production of A2E. These include restricting all-trans-retinal production by limiting light transition and reducing vitamin A (all-trans-retinol) intake, increasing vitamin A excretion, and using inhibitors to prevent vitamin A transport into the eye. The drug ALK-001, for example, is currently being evaluated in a double-blind, placebocontrolled, clinical trial in Stargardt disease (ClinicalTrials.gov identifier: NCT02402660). ALK-001 can mitigate the formation of bisretinoids and other oligomers of vitamin A without depriving the photoreceptors of vitamin A or modifying the concentration of ocular retinaldehyde. 57 
Best Vitelliform Macular Dystrophy
Best vitelliform macular dystrophy (BVMD), or Best1 disease, is commonly inherited in an autosomal dominant fashion with variable penetrance and expressivity caused by mutations in BEST1, a gene that transcribes the bestrophin-1 protein, located on the basolateral membrane of RPE cells. 58 This protein operates as a Ca 2+ -sensitive chloride channel. 59 However, the pathogenesis and mechanism leading from bestrophin-1 dysfunction to lipofuscin accumulation and retinal damage still remains unclear. 60 Histopathologic studies have revealed that typical findings include RPE degeneration and deposition of abnormal accumulations of lipofuscin inside the RPE cells and within the sub-RPE space. 61 Typically, fundus abnormalities are bilateral and visible within the first 2 decades of life (Fig. 3) . 62 The vitelliform macular lesion can present asymptomatically or associated with visual symptoms such as reduced visual acuity and metamorphopsia. 61 Gass 63 described that BVMD lesions develop in stages: subclinical, vitelliform, pseudohypopyon, vitelliruptive (scrambled egg), and atrophic. On examination, the early BVMD stage appears with a dome-shaped, well delineated, fluid-filled (vitelliform), egg yolk-like lesion in the macula that is markedly intense on FAF (Fig. 3) . 64 Over time, the material in the subretinal space becomes less homogeneous with alteration in pigmentation, and later the material may disappear leading to atrophy of the RPE. 65 Fundus autofluorescence shows hyperautofluorescence corresponding to lipofuscin accumulation and hypoautofluorescence in areas of RPE atrophy. 66 Complications such as hemorrhagic detachment and choroidal neovascularization (CNV) can occur at each stage and are difficult to diagnose clinically.
Electrooculogram (EOG) helps to establish the diagnosis as it shows a reduced Arden ratio (light rise peak divided by dark trough). Full-field ERG is usually normal as BVMD patients maintain normal peripheral fundus and vision, but in late stages, the photopic ERG can sometimes be slightly decreased. 67 Spectral domain OCT findings are typically localized to the subretinal space but the extension will vary according to the duration and size of the lesion. Initially, at the vitelliform stage, there is a shallow elevation with high reflectance beneath neurosensory retina, but in the advanced stages, outer retinal layers disappear, corresponding to atrophy. 63, 64 To date, there is no treatment for BVMD, but recent studies aim to create RPE from induced pluripotent stem cells (iPS-RPE). These studies aim to correct the mutated allele with the wild-type allele in the iPS-RPE cells through genome surgery techniques and then implanting the wild-type cells into the retina. 67, 68 Antivascular endothelial growth factor has been used in the treatment of CNV complications, although it is not clear whether outcomes are improved with intervention as compared with conservative management.
OTHER DISEASES X-linked Juvenile Retinoschisis
X-linked retinoschisis (XLRS) is the leading cause of juvenile macular degeneration in males with an estimated prevalence of between 1 in 15,000 and 1 in 30,000. 69, 70 It is caused by mutations in the RS1 gene, which encodes the retinal protein retinoschisin. 71 Retinoschisin is implicated in cell-to-cell interactions and cell adhesion, and alterations lead to schisis (splitting) of the inner retinal layers.
Patients often present at school age with poor vision and reading difficulties, although this can vary with patients presenting as early as 3 months of age. 72 Less commonly, the disorder may present in early infancy with squinting, nystagmus, and bilateral, highly elevated bullous retinoschisis, often with hemorrhage within the schisis cavity or into the vitreous. 73 Visual function is often stable from infancy to the 40s, when deterioration occurs. However, complications, including vitreous hemorrhage (up to one third of patients) and retinal detachment (up to 20% of patients), can lead to severe visual loss. 74 Foveal schisis is the characteristic sign of XLRS and is present in 98-100% of cases. Peripheral retinoschisis is often noted in the inferotemporal region and is present in more than 50% of patients. 74 The clinical diagnosis of XLRS can be challenging, as subtle foveal schisis can be difficult to observe with the ophthalmoscope but may be more apparent on red-free fundus photography. Electrodiagnostic testing is useful in either supporting or suggesting the diagnosis. Patients with XLRS show a characteristic pattern on ERG: a reduction in the amplitude of the b-wave and a relative preservation of the negative a-wave, referred to as an electronegative ERG. Reduced b-wave amplitudes indicate an inner retinal abnormality. 75 Spectral domain OCT is also useful for diagnosing XLRS, as the scans show the splitting of the retina, which in many cases involves more than 1 layer (Fig. 3 ). An important advantage of SD-OCT is that it can show splitting of retinal layers even when not observed upon fundoscopy. Genetic testing is crucial, as identifying the mutation not only confirms the diagnosis but is also the basis for genetic counseling.
There is no cure for XLRS. To reduce macular cysts and retinal thickness, the use of topical carbonic anhydrase inhibitors has shown efficacy when evaluated by SD-OCT, but little improvement in visual acuity has been seen. 76, 77 Progress towards treatment has been seen in preclinical studies with rs1 knockout mice and AAV therapy. 78, 79 Clinically, there is a phase 1/2a clinical trial underway for AAV-RS1 (ClinicalTrials.gov identifier: NCT02317887).
CONCLUSIONS
Diagnosis of the specific IRD is crucial, especially in the pediatric population, as the diagnosis may dictate visual prognosis and future plans for the affected patient. In addition, the correct diagnosis can indicate potential associations with syndromes that manifest with other disabling systemic diseases. A thorough pedigree and family medical history along with an ERG are critical in helping the clinician make the correct diagnosis. Importantly, with advances in high-throughput DNA sequencing technologies, gene sequencing has become another important tool for IRD diagnosis. Although there is currently no treatment for these diseases, the advent of gene therapy and current gene therapy trials offer future hope for the affected population in addressing this unmet need for treatment.
